BriaCell hires firms to assess commercial potential of Bria-IMT

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) has engaged two consulting firms to evaluate the commercial and market access potential of its cancer therapy candidate Bria-IMT, according to a press release from the clinical-stage biotechnology company.

Charles River Associates (Nasdaq: CRAI) has been retained to assess epidemiology, pricing, prescriber dynamics, and market access potential for Bria-IMT in metastatic breast cancer in the United States. Separately, Kaleio, Inc. has been engaged to support brand strategy and commercial-readiness planning.

Bria-IMT is currently being evaluated in a pivotal Phase 3 clinical trial (NCT06072612) in metastatic breast cancer and has not received regulatory approval. BriaCell described the engagements as a commercial-readiness step in preparation for potential future commercialization, contingent on successful clinical development and regulatory approvals.

You May Also Be Interested In

• GameStop CEO Cohen buys 1.15M shares
• BrightSpire Capital prices $960 million CRE CLO, to redeem 2024 deal
• Alibaba (BABA) Targets 20gw Of Data Center Capacity By 2032 - Bloomberg